30
Participants
Start Date
January 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
August 31, 2013
G-202
Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison
University of Texas, Health Science Center,Cancer Therapy and Research Center, San Antonio
Lead Sponsor
GenSpera, Inc.
INDUSTRY